Effect of intramuscular cholecalciferol megadose in children with nutritional rickets
Bothra M, Gupta N, Jain V
Journal of pediatric endocrinology & metabolism : JPEM · 8 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2016-01-01 · J Pediatr Endocrinol Metab · vol. 29 · issue 6 · pp. 687–92
- Publisher
- De Gruyter
- Cited
- 10 citations · more than 73% of similar papers · 0.9× the field average
- References
- 24 works
- Access
- Paywalled
- Research areas
- Vitamin D Research Studies · Bone health and osteoporosis research · Vitamin K Research Studies
- Keywords
- Medicine, Rickets, Cholecalciferol, Vitamin D and neurology, Hypervitaminosis, vitamin D deficiency, Vitamin, Intramuscular injection, Internal medicine, Pediatrics, Endocrinology
- MeSH
- humans, rickets, cholecalciferol, parathyroid hormone, alkaline phosphatase, vitamin d, injections, intramuscular, adolescent, child, child, preschool, infant, female, male
3 authors
From IN
- Meenakshi BothraAll India Institute of Medical Sciences
- Nandita GuptaAll India Institute of Medical Sciences
- Vandana Jain · correspondingAll India Institute of Medical Sciences
Abstract
Background
The treatment practices for vitamin D deficiency rickets are highly variable. Though a single intramuscular (IM) megadose of vitamin D is economical, and ensures good compliance, it poses the risk of hypervitaminosis D. This observational study was conducted to assess the duration of effect and safety of single IM megadose of cholecalciferol in the treatment of vitamin D deficiency rickets.
Methods
Children younger than 14 years with rickets were enrolled. Baseline investigations included radiograph of wrists and estimation of serum calcium, phosphate, alkaline phosphatase (ALP), 25(OH) vitamin D and parathormone (PTH) levels. All children received a single IM megadose of vitamin D3. Biochemical parameters were re-evaluated at 1.5, 3 and 6 months after the megadose and the values were compared to the baseline.
Results
We enrolled 21 children, out of which nine remained under active follow-up till 6 months. Radiological evidence of rickets was present in all 21 children, 14 had hypocalcemia at the time of presentation. After IM cholecalciferol megadose, median 25 hydroxy vitamin D [25(OH)D] level remained significantly more than the baseline till 6 months after the megadose. At 1.5 months after the vitamin D megadose, three (30%) of the children were found to develop toxic levels of vitamin D (>150 ng/mL), although none had hypercalcemia or any clinical manifestation of vitamin D toxicity. At 3 months and 6 months after the megadose, 25(OH)D levels remained in the sufficient range (20-100 ng/mL) in seven out of the eight children who came for follow-up.
Conclusions
A single IM megadose of vitamin D may be effective in significantly increasing the 25(OH)D levels for at least 6 months in children with rickets, but elevation of 25(OH)D to toxic range raises concern regarding its safety.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.